COVID-19 thorough review of the vaccine by Pfizer and its partner BioNTech was published by the Food and Drug Administration on Tuesday morning in the run-up to a conference of independent experts on Thursday to counsel the Department on whether to give the vaccine an emergency use permit.
The Agency's review found "no specific safety concerns identified that would preclude the issuance of a EUA."Severe responses have been infrequent. However, side effects are prominent, with most research participants suffering injection site reactions, headaches, and fatigue.
The study further supports the 95 percent vaccine efficacy previously reported, measured a week after two vaccine doses. The doses of the vaccine are delivered 21 days apart.
The clinical data also indicate that after the first injection, the vaccine could be able to resist COVID-19, 82 percent safe, but the FDA review says the evidence available does not make a definite conclusion on that possible effect.
'For successful immunization for the prevention of COVID-19 caused by SARS-CoV-2 in people 16 years of age and over is the vaccination authorization under consideration.
In an open public workshop, the Vaccinations and Associated Biological Products Advisory Committee, an advisory group, will address the vaccine on Thursday.
The Department would ask scientists to determine whether the scientific data available confirms the vaccine's potential emergency use. In specific, the Committee will be asked if the vaccine's known and possible benefits outweigh its known and potential risks in persons 16 and older.
The FDA will also invite the experts to suggest whether further tests can be carried out by the firms in order to better explain the safety and efficacy of the vaccine after it has been made available under the EUA.
